?

Sleep Apnea - Pipeline Review, H2 2014

Date: December 31, 2014
Pages: 52
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S547F9C6CA9EN
Leaflet:

Download PDF Leaflet

Sleep Apnea - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Sleep Apnea - Pipeline Review, H2 2014’, provides an overview of the Sleep Apnea’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Sleep Apnea and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Sleep Apnea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Sleep Apnea pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Sleep Apnea Overview
Therapeutics Development
Pipeline Products for Sleep Apnea - Overview
Pipeline Products for Sleep Apnea - Comparative Analysis
Sleep Apnea - Therapeutics under Development by Companies
Sleep Apnea - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Sleep Apnea - Products under Development by Companies
Sleep Apnea - Companies Involved in Therapeutics Development
Cortex Pharmaceuticals, Inc.
Galleon Pharmaceuticals
Rottapharm SpA
SK Biopharmaceuticals Co., Ltd.
Sleep Apnea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CX-1739 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-2007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-2076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexloxiglumide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
doxapram hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GAL-021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GAL-160 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GAL-160 Backups - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itriglumide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SKL-N05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sleep Apnea - Recent Pipeline Updates
Sleep Apnea - Dormant Projects
Sleep Apnea - Discontinued Products
Sleep Apnea - Product Development Milestones
Featured News & Press Releases
Sep 02, 2014: Galleon Pharmaceuticals Announces Publication of Proof-of-Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic
Jan 06, 2014: Galleon Scientists Win Prestigious Research Awards for First-in-Class Treatment of Emerging Perioperative Sleep Apnea Epidemic
Apr 11, 2013: Galleon Pharma's GAL-021 Demonstrates Positive Results In Clinical Proof-of-Concept Study
Mar 13, 2012: Cortex Reports Issuance Of Patents For Next Generation Of Ampakine Compounds
Mar 13, 2012: Cortex Obtains Patents For Next Generation Of Ampakine Compounds
Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739
Feb 02, 2011: Cortex’s Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Sleep Apnea, H2 2014
Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Sleep Apnea - Pipeline by Cortex Pharmaceuticals, Inc., H2 2014
Sleep Apnea - Pipeline by Galleon Pharmaceuticals, H2 2014
Sleep Apnea - Pipeline by Rottapharm SpA, H2 2014
Sleep Apnea - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Sleep Apnea Therapeutics - Recent Pipeline Updates, H2 2014
Sleep Apnea - Dormant Projects, H2 2014
Sleep Apnea - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Sleep Apnea, H2 2014
Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

Cortex Pharmaceuticals, Inc.
Galleon Pharmaceuticals
Rottapharm SpA
SK Biopharmaceuticals Co., Ltd.
Skip to top


Sleep Apnea - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages
Sleep Apnea - Pipeline Review, Q1 2011 US$ 500.00 Jan, 2011 · 32 pages
Sleep Apnea - Pipeline Review, Q3 2011 US$ 500.00 Jul, 2011 · 65 pages
Sleep Disorders - Pipeline Review, Q3 2011 US$ 500.00 Jul, 2011 · 136 pages

Ask Your Question

Sleep Apnea - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: